Can Bydureon Bounce Back? Amylin’s Proposed Cardio Safety Trial Is A Faster Option
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amylin Pharmaceuticals Inc. confirmed that it is awaiting word from FDA regarding a proposed trial design for a cardiac safety study that involves a continuous infusion of exenatide. Amylin needs the study in order to resubmit the NDA for its once-weekly subcutaneous injectable Bydureon (long-acting exenatide), which it plans to do by year-end.
You may also be interested in...
Victoza Sales Lift Novo Nordisk 2010 Forecasts
Strong Victoza roll-out and setback to Bydureon help boost outlook for Novo Nordisk.
Amylin Plans Cardiac Safety Study By The Book After Bydureon Rejection
There’s more than meets the eye to the story of the seemingly surprising "complete response" letter for Amylin’s ultra-high-profile once-weekly diabetes injectable Bydureon.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.